Cytolytic mechanisms and T-cell receptor Vβ usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes

Immunology

Volumn 127, Issue 4, 2009, Pages 577-586

  Vanhoutte, Victoria J ^a   McAulay, Karen A ^a   McCarrell, Erin ^b   Turner, Marc ^c   Crawford, Dorothy H ^a   Haque, Tanzina ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Centre for Virology   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Cytolytic pathways; Cytotoxic T lymphocytes; Epstein Barr virus; T cell receptor

Indexed keywords

CALCIUM; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CONCANAMYCIN A; EGTAZIC ACID; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; L SELECTIN; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL TRANSFORMATION; CLONAL VARIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME RELEASE; EPSTEIN BARR VIRUS; EXOCYTOSIS; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; GRANZYMES; HUMANS; IMMUNOPHENOTYPING; PERFORIN; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67650487173     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.03035.x     Document Type: Article

References (21)

1. Babcock GJ, Decker LL, Volk M et al. EBV persistence in memory B cells in vivo. Immunity 1998 9 : 395 404. (Pubitemid 28462760)
2. Macsween KF, Crawford DH. Epstein-Barr virus - recent advances. Lancet Infect Dis 2003 3 : 131 40.
3. Moss DJ, Burrows SR, Silins SL et al. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001 356 : 475 88.
4. Steven NM, Annels NE, Kumar A et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997 185 : 1605 17.
5. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004 4 : 595 602.
6. Münz C, Bickham KL, Subklewe M et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000 191 : 1649 60.
7. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 2004 18 : 193 209. (Pubitemid 38859629)
8. Rooney CM, Ng CYC, Loftin S et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 : 9 13.
9. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV) -specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002 99 : 2592 8.
10. Sherritt MA, Bharadwaj M, Burrows JM et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003 75 : 1556 60.
11. Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002 360 : 436 42.
12. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007 110 : 1123 31.
13. Wilkie GM, Taylor C, Jones MM et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother 2004 27 : 309 16.
14. Rozen S, Skaletsky J. Primer3 on the WWW for general users and for biologist programmers. In : Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa : Humana Press, 2000 : 385 6.
15. Foster AE, Marangolo M, Sartor MM et al. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004 104 : 2403 9.
16. Callan MF, Steven N, Krausa P et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996 2 : 906 11.
17. Callan MF, Fazou C, Yang H et al. CD8(+) T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest 2000 106 : 1251 61.
18. Pantaleo G, Soudeyns H, Demarest JF et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997 94 : 9848 53.
19. Metkar SS, Wang B, Aguilar-Santelises M et al. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 2002 16 : 417 28.
20. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005 79 : 4896 907.
21. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008 8 : 247 58.